(Q36668224)

15 August 2017

1 reference

title

Cetuximab in the treatment of head and neck cancer (English)

1 reference

15 August 2017

1 reference

Jacques Bernier

1

1 reference

15 August 2017

publication date

1 November 2006

1 reference

Expert Review of Anticancer Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1539-1552

1 reference

Global cancer statistics, 2002

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Promising new advances in head and neck radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

The expanding role of systemic therapy in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Dysphagia following chemoradiation for locally advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

The epidermal growth factor receptor mediates radioresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Epidermal growth factor receptor directed therapy in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Targeting signal transduction pathways in colorectal cancer--more than skin deep

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

The EGFR as a target for anticancer therapy--focus on cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiothera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Epidermal growth factor receptor dependence in human tumors: more than just expression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1539

10.1586/14737140.6.11.1539

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference